Researchers found when ribociclib, a targeted therapy drug, is added to hormone therapy there are a significant invasive disease-free survival benefit in patients with early hormone-receptor (HR) positive/HER2 negative breast cancer. Researchers found that patients who took the combination therapy had substantially longer invasive disease-free survival compared to those who were treated with the hormone therapy alone, regardless of whether the cancer has spread to the lymph nodes. The addition of the targeted therapy reduced the risk of recurrence by 25%. "The results from the clinical trial have immediate implications for patients," said Slamon. "The findings show this combination is...